Ocular toxoplasmosis in a patient treated with ustekinumab for psoriasis

Clin Exp Dermatol. 2020 Aug;45(6):802-804. doi: 10.1111/ced.14198. Epub 2020 Mar 25.

Authors

S Javadzadeh¹, M A Gkini¹, G D Panos², T Adewoyin², A Bewley¹

Affiliations

¹ Dermatology Department, Whipps Cross University Hospital, Barts Health NHS Trust, London, UK.
² Eye Treatment Centre, Whipps Cross University Hospital, Barts Health NHS Trust, London, UK.

PMID: 32212270
DOI: 10.1111/ced.14198

No abstract available

Publication types

Case Reports

MeSH terms

Antibiotic Prophylaxis / methods
Antibodies, Monoclonal, Humanized / adverse effects
Antibodies, Monoclonal, Humanized / therapeutic use
Chorioretinitis / diagnosis
Chorioretinitis / etiology
Dermatologic Agents / administration & dosage
Dermatologic Agents / adverse effects
Dermatologic Agents / therapeutic use
Female
Fundus Oculi
Humans
Injections, Subcutaneous
Middle Aged
Psoriasis / drug therapy*
Recurrence
Tomography, Optical Coherence / methods
Toxoplasma / isolation & purification
Toxoplasmosis, Ocular / diagnosis*
Toxoplasmosis, Ocular / drug therapy
Toxoplasmosis, Ocular / etiology
Ustekinumab / administration & dosage
Ustekinumab / adverse effects*
Ustekinumab / therapeutic use

Substances

Antibodies, Monoclonal, Humanized
Dermatologic Agents
Ustekinumab